Table 1.
Bivariate and multivariate analysis of clinical characteristics
| Characteristic | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Patients, n (%) | OR (95% CI) | p value | OR (95% CI) | p value | ||
| MSP | MRP | |||||
| Age | ||||||
| 50–59 | 28 (56.00) | 22 (44.00) | – | – | – | |
| 60–69 | 32 (35.56) | 58 (64.44) | 2.29 (1.13–4.70) | 0.0212 | 1.75 (0.68–4.61) | 0.2470 |
| ≥ 70 | 21 (28.77) | 52 (71.23) | 3.11 (1.47–6.74) | 0.0029 | 0.69 (0.21–2.13) | 0.5246 |
| Gender | ||||||
| Female | 49 (44.55) | 61 (55.45) | – | – | – | |
| Male | 32 (31.07) | 71 (68.93) | 1.78 (1.01–3.14) | 0.0445 | 1.56 (0.66–3.74) | 0.3102 |
| Lesion | ||||||
| Mild | 42 (52.50) | 38 (47.50) | – | – | – | – |
| Moderate | 20 (39.22) | 31 (60.78) | 1.70 (0.84–3.53) | 0.1434 | 1.33 (0.45–3.88) | 0.6012 |
| Severe | 19 (23.17) | 63 (76.83) | 3.62 (1.86–7.26) | 0.0001 | 3.84 (1.44–10.81) | 0.0084 |
| High blood pressure | ||||||
| No | 52 (34.43) | 99 (65.56) | – | – | – | |
| Yes | 29 (46.77) | 33 (53.23) | 0.60 (0.33–1.10) | 0.0972 | 0.36 (0.14–0.87) | 0.0266 |
| Diabetes | ||||||
| No | 73 (39.67) | 111 (60.33) | – | – | ||
| Yes | 8 (27.59) | 21 (72.41) | 1.70 (0.74–4.33) | 0.2195 | ||
| CHD | ||||||
| No | 73 (37.82) | 120 (62.18) | – | – | ||
| Yes | 8 (39.60) | 12 (60.40) | 0.91 (0.35–2.45) | 0.8423 | ||
| Cancers | ||||||
| No | 78 (38.24) | 126 (61.76) | 0.83 (0.16–3.34) | 1.0000 | ||
| Yes | 3 (33.33) | 6 (66.67×) | ||||
| Prior antiviral drugs | ||||||
| No | 41 (36.61) | 71 (63.39) | – | – | ||
| Yes | 40 (40.00) | 61 (60.00) | 0.88 (0.50–1.54) | 0.8812 | ||
| Family history | ||||||
| Yes | 72 (37.11) | 122 (62.89) | – | – | ||
| No | 9 (47.37) | 10 (52.63) | 0.66 (0.25–1.75) | 0.3918 | ||
| Location | ||||||
| V1–3 | 6 (20.00) | 24 (80.00) | – | – | – | |
| C1–8 | 17 (44.74) | 21 (5.26) | 0.32 (0.10–0.93) | 0.0360 | 0.28 (0.06–1.12) | 0.0783 |
| T1–12 | 42 (37.17) | 71 (62.83) | 0.43 (0.15–1.09) | 0.0775 | 0.53 (0.15–1.74) | 0.3083 |
| C1–T12 | 9 (52.94) | 8 (47.06) | 0.23 (0.06–0.85) | 0.0276 | 0.43 (0.07–2.34) | 0.3346 |
| L1–5 | 3 (75.00) | 1 (25.00) | 0.10 (0.00–1.01) | 0.0478 | 0.42 (0.02–6.22) | 0.5359 |
| S1–5 | 1 (33.33) | 2 (66.67) | 0.49 (0.03–17.11) | 0.5235 | 0.46 (0.01–25.21) | 0.7015 |
| L1–S5 | 3 (37.50) | 5 (62.50) | 0.42 (0.07–2.71) | 0.3631 | 0.60 (0.04–10.03) | 0.7104 |
| Phase | ||||||
| AHZ | 70 (57.85) | 51 (42.15) | – | – | ||
| SHZ | 10 (18.18) | 45 (81.82) | 6.05 (2.87–13.85) | < 0.0001 | 8.95 (3.15–29.48) | 0.0001 |
| PHN | 1 (2.70) | 36 (97.30) | 42.74 (8.84–1026.39) | < 0.0001 | 2.37e8 (6.57e−9–1.45e160) | 0.9845 |
| VAS | – | – | 0.95 (0.78–1.16) | 0.5990 | ||
| McGill | – | – | 1.05 (1.01–1.10) | 0.0328 | ||
| PSQI | – | – | 1.07 (1.00–1.14) | 0.0369 | ||
| PHQ9 | – | – | 1.09 (1.03–1.16) | 0.0023 | 1.10 (1.00–1.20) | 0.0447 |
| Anxiety | – | – | 1.01 (0.99–1.03) | 0.2130 | ||